CAS: 111025-46-8; 5-(4-(2-(5-Ethylpyridin-2-yl)Ethoxy)Benzyl)Thiazolidine-2,4-Dione

上下游产品

5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2-imino-4-thiazolidinone 5-{4-[2-(5-ethyl-pyridin-2-yl)ethoxy]benzylidene}-2,4-thiazolidinedione 5-ethyl-2-(2-hydroxyethyl)pyridine 4-fluorobenzonitrile3-(2-biphenyl-4-yl-2-oxo-ethyl)-5-{4-[2-(5-ethyl-pyridin-2-yl)-ethoxy]-benzyl}-thiazolidine-2,4-dione (R)-5-({p-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione L-tartrate (5R)-5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione tosylate

4-(乙烯基氧基)苯甲醛置于哌啶,环己硫醇,(4,4'-二叔丁基-2,2'-联吡啶)双[(2-吡啶基)苯基]铱(III)六氟磷酸盐,二氢吡啶,氯化铵,Sodium Hydroxide体系中,用 甲醇,乙醇,2,2,2-三氟乙醇,水 用作溶剂,化学反应 37.5H,反应生成5-[[4-[2-(5-乙基吡啶-2-基)乙氧基]苯基]甲基]-1,3-噻唑烷-2,4-二酮
参考文献:官能化烯烃的自由基加氢芳基化和光催化吡啶自由基反应的机理研究
标题:官能化烯烃的自由基加氢芳基化和光催化吡啶自由基反应的机理研究
摘要:我们报告了使用功能化烯烃和炔烃构建块的卤代吡啶的光氧化还原烷基化.卤化吡啶的选择性单电子还原提供了相应的杂芳基,这些杂芳基与烯烃底物发生反马尔科夫尼科夫加成.该系统表现出温和且耐受各种烯烃和炔烃亚型.计算和实验研究的结合支持涉及质子耦合电子转移的机制,然后是介质依赖性烯烃加成和由极性反转催化剂介导的快速氢原子转移.
Doi:10.1021/jacs.8B10238

专利信息

专利号:US-10005720-B2
优先权日:2013-04-05
标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
发明人：SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

专利号:WO-2009148195-A1
优先权日:2008-06-02
标题:5-(4-hydroxybenzyl)thiazolidine-2,4-dione as intermediate for synthesis of thiazolidinedione based compounds and process for preparing the same
发明人：PARK JIN OH; KIM YONG GIL; SON HAN IL; LEE YUN JEONG; KIM EUN MI
权利人:DAEBONG LS LTD; PARK JIN OH; KIM YONG GIL; SON HAN IL; LEE YUN JEONG; KIM EUN MI
摘要:The present invention relates to 5-(4-hydroxybenzyl)thiazolidine-2,4-dione represented by the following Chemical Formula [1], which is useful as an intermediate for synthesis of thiazolidinedione based compounds, a method for preparing the compound, and a method for preparing pioglitazone or pioglitazone hydrochloride, which is a thiazolidinedione based drug and useful in treating and preventing diabetes, using the 5-(4-hydroxybenzyl)thiazolidine-2,4-dione represented by Chemical Formula [1] as an intermediate:

专利号:EP-1694646-B1
优先权日:2003-12-19
标题 :Process for the synthesis of pioglitazone hydrogen chloride
发明人：FISCHER JANOS; FODOR TAMAS; LEVAI SANDOR; PETENYI ENDRENE; PERENYI EVA
权利人:RICHTER GEDEON VEGYESZET
摘要:The invention relates to a process for the synthesis of pioglitazone hydrogen chloride - which is an antidiabetic drug - via novel intermediates by reacting 4-[2-(5-ethyl-2-pyridinyl)-ethoxy]-benzaldehyde salt of formula (II), wherein HX is: HCI, CF3COOH, C4H4O4, (COOH)2 with a base and then thiazolidine-2,4-dione, and the obtained 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methylene]-2,4-thiazolidinedione base is treated with hydrochloric acid and the obtained 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl] methylene]-2,4-tiazolidinedione hydrogen chloride of formula(III) is hydrogenated in the presence of a catalyst. Further objects of the invention are the salts of general formula (II) and the benzylidene derivative of formula (III).

专利号:US-2025235415-A1
优先权日:2022-02-23
标 题:Modulation of human breast milk composition
发明人：ROSS MICHAEL G; DESAI MINA
权利人:LUNDQUIST INST FOR BIOMEDICAL INNOVATION AT HARBOR UCLA MEDICAL CENTER
摘要:Compositions and methods for improving a child, such as an infant's health, are provided. The methods entail improving the quality of breast milk in a female human individual that provides breast milk, or expects to provide breast milk, to the child, by administering to the individual an agent that increases the individual's sensitivity to insulin, and/or an agent that reduces the substrate uptake, synthesis or secretion of long chain fatty acids, reduces the substrate uptake, synthesis or secretion of short chain fatty acids, increases the amino acid uptake, protein synthesis or protein secretion of proteins, or reduces the uptake or synthesis of lactose.

专利号:US-2008287407-A1
优先权日:2003-12-10
标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
发明人：GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
权利人:NITROMED INC
摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

专利号:US-2009053804-A1
优先权日:2007-07-27
标题:Methods of reducing intracellular fats from mammalian cells
发明人：RUIZ JOSEPH CHARLES
权利人:VESTA THERAPEUTICS INC
摘要:The present invention provides methods of reducing or clearing fat from mammalian cells. The method comprises culturing the cells in an environment that facilitates: 1) reduction of de novo fatty acid synthesis, 2) activation or synthesis of fatty acid oxidizing enzymes, and/or 3) export of lipids out of the cells. Cells substantially free of fatty acid are also provided in this invention.